Literature DB >> 1810101

Early detection of ovarian cancer: preliminary results of the Yale Early Detection Program.

P E Schwartz1, J T Chambers, K J Taylor, J Pellerito, L Hammers, L A Cole, T L Yang-Feng, P Smith, S T Mayne, R Makuch.   

Abstract

Eighty-four women at high risk for ovarian cancer by having first-degree relatives with epithelial ovarian cancer participated in a newly established, early ovarian cancer detection program at Yale University. Participants were to be evaluated with physical examinations and circulating tumor markers at entry and every six months thereafter. Endovaginal ultrasound and color Doppler flow studies were to be performed at three and nine months following entry into the program. In addition, women were encouraged to follow American Cancer Society guidelines for mammography. Stool was checked for occult blood. Endometrial sampling was offered to post-menopausal women. No participant has developed an ovarian cancer since entering the program. One woman has been diagnosed to have breast cancer. False-positive levels of circulating tumor markers (CA 125, 4/84 [4.8 percent]; lipid-associated sialic acid in plasma, 13/84 [15.5 percent]; NB/70K, 4/84 [4.8 percent]; and urinary gonadotropin fragment, 1/65 [1.5 percent]) were observed on entry into the program. Low resistive indices (less than 0.5) were documented in 8/91 (8.8 percent) ovaries studied by the color Doppler flow technique. One participant underwent a laparotomy based on a false-positive endovaginal ultrasound examination. Tests now being employed in community practice have a high likelihood of being associated with false-positive results. Therapeutic interventions based on isolated abnormal tumor markers or ultrasound studies obtained from women with family histories of ovarian cancer may lead to inappropriate surgery. It is necessary for cancer centers to develop expertise in ovarian cancer detection techniques to advise physicians in their geographic areas appropriately about the significance of the abnormal screening test.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810101      PMCID: PMC2589423     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  8 in total

1.  Clinical evaluation of ovarian tumor antigen NB/70K: monoclonal antibody assays for distinguishing ovarian cancer from other gynecologic disease.

Authors:  S Knauf
Journal:  Am J Obstet Gynecol       Date:  1988-05       Impact factor: 8.661

2.  Urinary gonadotropin fragment, a new tumor marker. I. Assay development and cancer specificity.

Authors:  J H Nam; L A Cole; J T Chambers; P E Schwartz
Journal:  Gynecol Oncol       Date:  1990-03       Impact factor: 5.482

3.  Familial Ovarian Cancer Registry.

Authors:  M S Piver; C J Mettlin; Y Tsukada; P Nasca; P Greenwald; M E McPhee
Journal:  Obstet Gynecol       Date:  1984-08       Impact factor: 7.661

Review 4.  Epidemiology and etiology of ovarian cancer: a review.

Authors:  A P Heintz; N F Hacker; L D Lagasse
Journal:  Obstet Gynecol       Date:  1985-07       Impact factor: 7.661

5.  Circulating tumor markers in the monitoring of gynecologic malignancies.

Authors:  P E Schwartz; S K Chambers; J T Chambers; J Gutmann; N Katopodis; R Foemmel
Journal:  Cancer       Date:  1987-08-01       Impact factor: 6.860

6.  Monoclonal antibody assays for measuring ovarian tumor antigen in blood. Detection of NB/70K in patients with ovarian cancer and nongynecologic diseases.

Authors:  S Knauf
Journal:  Cancer       Date:  1988-09-01       Impact factor: 6.860

7.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

8.  Lipid-associated sialic acid test for the detection of human cancer.

Authors:  N Katopodis; Y Hirshaut; N L Geller; C C Stock
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.